drugset / Trial / NCT00661362

Evaluate Efficacy and Safety of Saxagliptin in Combination With Metformin in Adult Patients With Type 2 Diabetes

NCT00661362

Phase 3 Completed 570 enrolled AstraZeneca Bristol-Myers Squibb · collab
RandomizedParallel-groupQuadruple-blindTreatment

Summary

Saxagliptin is a new investigational medication being developed for treatment of type 2 diabetes. This study is designed to evaluate the efficacy and safety in adult patients who have inadequate glycaemic control when treated with metformin in addition to diet and exercise.

Timeline

Start
2008-06
Primary completion
2009-09
Completion
2009-09

Drugs

EvaluationDrugModalityDoseRoute
Subject SAXAGLIPTIN ANHYDROUS Small molecule 5 mg Oral
Background Metformin Small molecule Oral